Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CKD 702

Next Previous
Drug Profile

CKD 702

Alternative Names: CKD-702

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; National Cancer Center (Korea)
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 25 Apr 2025 CKD 702 is still in phase I trials for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV) (NCT04667975)
  • 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top